Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 431.50K | -135.00K | -135.00K | 621.00K | 95.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.32M | 391.00K | 391.00K | 1.15M | 608.90K |
| Operating Income | -1.32M | -391.00K | -391.00K | -1.15M | -608.90K |
| Income Before Tax | -3.25M | -112.70K | -112.70K | -1.81M | -1.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.25M | -112.70K | -112.70K | -1.81M | -1.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.25M | -112.70K | -112.70K | -1.81M | -1.23M |
| EBIT | -1.32M | -391.00K | -391.00K | -1.15M | -608.90K |
| EBITDA | -1.32M | -387.30K | -387.30K | -1.15M | -601.40K |
| EPS Basic | -0.12 | -0.01 | -0.01 | -12.96 | -8.83 |
| Normalized Basic EPS | -0.07 | -0.01 | -0.01 | -6.48 | -4.06 |
| EPS Diluted | -0.12 | -0.01 | -0.01 | -12.96 | -8.83 |
| Normalized Diluted EPS | -0.07 | -0.01 | -0.01 | -6.48 | -4.06 |
| Average Basic Shares Outstanding | 28.22M | 17.86M | 17.86M | 139.30K | 139.30K |
| Average Diluted Shares Outstanding | 28.22M | 17.86M | 17.86M | 139.30K | 139.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |